Dr. Krisztina Gecse, assistant lecturer of the 1st Department of Internal Medicine gave a presentation on unique Hungarian research results in the field of IBD (inflammatory bowel disease) at the Oxford MasterClass 2015. In her presentation “Biosimilars: first or last?” she demonstrated the results of a joint research carried out by the biological centres in Hungary, which examined infliximab efficiency in inflammatory bowel diseases. The research proved that this medication is used effectively and safely in case of inflammatory bowel diseases.
Dr. Krisztina Gecse was invited to the IBD MasterClass by its organiser, Professor Simon Travis.
“Hungary was among the first European countries to introduce biosimilar infliximab in the therapy of patients suffering from inflammatory bowel diseases.”, she said.
Biosimilars are biological medicines, which start to be offered on the market after the licence of the original reference product expires. The 1st Department of Internal Medicine started a prospective data collection in collaboration with other 12 Hungarian biological therapy centres.
“Up till now, the clinical application and efficiency of biosimilar infliximab in case of IBD had only been supported by a limited number of retrospective data.”, Dr. Krisztina Gecse said.
The national database and the research results confirmed the safe and efficient use of biosimilar infliximab in inflammatory bowel diseases.
Péter Pogrányi
Translated by: Ágnes Raubinek
